HRS4R
Vull donar

ALBERT MIGUELA BENAVIDES

Firma
ALBERT MIGUELA-BENAVIDES
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1

Projectes

Codi oficial: Estudio de biomarcadores moleculares neurodegeneración Data inici: 01/01/2022 Data fi: 30/06/2025 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: FRANCISCO SORIA MELGUIZO, S.A
Codi oficial: PI23/00517 Data inici: 01/01/2024 Data fi: 31/12/2026 Investigador/a principal: ANNA QUIROGA VARELA, LLUÍS RAMIÓ TORRENTÀ Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

Alemany-Perna, B, Tamarit, J, Cabiscol, E, Delaspre, F, Miguela, A, Huertas-Pons, JM, Quiroga-Varela, A, Ruiz, MM, Dominguez, DL, Torrenta, L, Genis, D, Ros, J

Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients

MOVEMENT DISORDERS, 2024, 39, 1099-1108 dx.doi.org/10.1002/mds.29808
Tortosa-Carreres J, Cubas-Núñez L, Quiroga-Varela A, Castillo-Villalba J, Ramió-Torrenta L, Piqueras M, Gasqué-Rubio R, Quintanilla-Bordas C, Sanz MT, Lucas C, Huertas-Pons JM, Miguela A, Casanova B, Laiz-Marro B, Pérez-Miralles FC

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 88, 105734-105734 dx.doi.org/10.1016/j.msard.2024.105734
Bravo, GCA, Quiroga-Varela, A, Gifreu, A, Pons, JMH, Lago, AB, Benavides, AM, Ramió-Torrentà, L

Echopraxia, an underrecognized clinical sign in multiple sclerosis: a biological and neuroimaging framework

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 743-743
Bravo, GCA, Gifreu, A, Quiroga-Varela, A, Lago, AB, Pons, JMH, Benavides, AM, Torrenta, LRI

First case of rebound effect after Ozanimod discontinuation

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 1081-1082
Pons, JMH, Coll-Martínez, C, Benavides, AM, Gifreu, A, Pont, JS, Bravo, GCA, Fulla, JG, Torrenta, LRI, Quiroga-Varela, A

Interleukin-8 plasma levels as a potential biomarker for predicting middle-term cognitive outcomes

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 976-977
Coll-Martínez, C, Pont, JS, Pons, JMH, Benavides, AM, Gifreu, A, Bravo, GCA, Quiroga-Varela, A, Ramió-Torrentà, L, Fulla, JG

Cognitive outcomes through MS disease course: 10-year follow-up

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 747-748
Coll-Martínez, C, Pons, JMH, Benavides, AM, Bravo, GCA, Gifreu, A, Pont, JS, Fulla, JG, Torrenta, LRI, Quiroga-Varela, A

Prognostic potential of plasma Interleukin-6 levels as biomarker for long-term cognitive performance

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 981-981
Benavides, AM, Pons, JMH, Coll-Martínez, C, Gifreu, A, Bravo, GCA, Torrenta, LRI, Quiroga-Varela, A

Circulating miR-197-3p and miR-1-3p in plasma as potential biomarkers of mitochondrial dysfunction in Primary Progressive Multiple Sclerosis

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 589-590
Gifreu-Fraixinó, A, Boix-Lago, A, Alvarez-Bravo, G, Quiroga-Varela, A, Miguela-Benavides, A, Huertas-Pons, JM, Coll-Martínez, C, Ramió-Torrentà, L

Effectiveness of high-efficacy disease-modifying therapies in naive patients with relapsing-remmiting multiple sclerosis compared with the escalation regimen

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 1089-1089
Quiroga-Varela, A, Pons, JMH, Coll-Martínez, C, Benavides, AM, Pont, JS, Gifreu, A, Bravo, GCA, Fulla, JG, Ramió-Torrentà, L

Exploring neurogranin as a potential biomarker for cognitive impairment and disease activity in multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 590-590

Formulari de contacte

Coneix l’IDIBGI!

menu